Biocon Biologics in Egypt
Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing.
It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.
Expanding Access to Lifesaving Therapies in AFMET
In the Africa-Midde East, Turkey (AFMET) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its commercialized biosimilars.
Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the AFMET region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia. The integrated insulins manufacturing and R&D facility in Malaysia, the largest in Asia, manufactures a broad portfolio of regular, basal, and rapid-acting insulins.
Focused on Making a Meaningful Difference in Egypt
In Egypt, Biocon Biologics operates in partnership with OnePharma Medics, SEDICO & MUP, leading pharmaceutical companies. Biocon Biologics is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease for the benefit of patients and improving healthcare outcomes in Egypt.
The company has seven commercialized products in Egypt — Hertraz (Trastuzumab), Ogivri (Trastuzumab), Abevmy (Bevacizumab), Fulphila® (Pegfilgrastim), Semglee (Insulin Glargine), Insulin H Mix (rh-Insulin) and Hulio® (Adalimumab). In line with our commitment to enable affordable access to insulins across the world, we have collaborated with SEDICO in Egypt to whom we are providing rh-Insulin Drug Substance. Our insulin is being marketed by our partner SEDICO as Insulin H Mix in Egypt.
Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner Viatris has further strengthened Biocon Biologics’ commercial presence in Egypt. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in Egypt, making a meaningful impact on patients’ lives.
In Egypt, rh-Insulin is commercialized by our partners SEDICO & MUP, Trastuzumab (Hertraz), Adalimumab, Insulin Glargine and Pegfilgrastim are commercialized by our partner OnePharma, and Trastuzumab (Ogivri) and Bevacizumab are commercialized by our partner SEDICO.
Commercialized Products
*rh-Insulin is commercialized by our partners SEDICO & MUP in Egypt.
**Trastuzumab (Ogivri) & Bevacizumab are commercialized by our partner SEDICO in Egypt.
*** Trastuzumab (Hertraz), Adalimumab, Insulin Glargine & Pegfilgrastim re commercialized by our partner OnePharma in Egypt.
Meet the Leaders
Delivering Highest-Quality Products Globally
80+
03
90+
Our Vision & Values
- Value creation through innovation and differentiation
- Collaboration, teamwork and mutual respect
- Performance-driven work culture
- Quality through compliance and best practices
- Integrity and ethical behaviour
The Biocon Advantage
*19th Annual Report of BioPlan Associates
